By investigating the interface of peripheral cytokines, namely IL-6 and brain cellular processes contributing to depression, one might be able to develop novel therapeutic options for treatment of mood disorders by sequestering and preventing this peripherally derived inflammatory marker from acting upon mood circuits in the CNS. This evidence concerns the gene IL6 and major depressive disorder.